Category - Executive Moves

Executive Moves

Karen Koski joins Oxford Immunotec as head of strategy

Oxford Immunotec Global (NASDAQ:OXFD) has appointed Karen Koski as head of strategy and investor relations, a newly created position that will report directly to CEO, Peter Wrighton-Smith. The appointment is effective...

June 7, 2017

Executive Moves

Ladenburg starts Catalyst at buy

Ladenburg Thalmann initiated coverage of Catalyst Biosciences (NASDAQ:CBIO) with a ‘buy” rating and $11.00 price target. The stock closed at $4.17 on June 5.

June 6, 2017

Executive Moves

Braeburn names Mike Derkacz as president, CEO

Closely held Braeburn Pharmaceuticals appointed Michael Derkacz as president and CEO, succeeding Behshad Sheldon, who is stepping down from both posts and as a director, effective immediately, but will continue to serve...

June 5, 2017

Executive Moves

Roth hires Eric Cheng to head healthcare investment banking

Closely-held Roth Capital Partners named Eric Cheng as managing director, head of healthcare investment banking.

April 27, 2017

Executive Moves

Duff & Phelps expands healthcare M&A team

Duff & Phelps has added managing director Phil Smith and director Adam Stormoen to its healthcare M&A advisory practice in Minneapolis. Mr. Smith has more than 25 years of healthcare transaction experience as an...

April 21, 2017

Executive Moves

3DS names Dr. Kevin Little as CSO

3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) appointed Dr. Kevin Little, a leading biomedical scientist and corporate executive, as its new chief scientific officer, effective immediately.

April 11, 2017

Executive Moves

John Calcagnini joins Stout as managing director

John Calcagnini has joined Stout Risius Ross as managing director in the investment banking group’s healthcare industry practice.

March 14, 2017

Executive Moves

Harry Glorikian joins 3D Signatures BAD

3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) has appointed Harry Glorikian to its business advisory board.

February 16, 2017

Executive Moves

Stereotaxis taps investor exec David Fischel as acting CEO

Stereotaxis (NASDAQ:STXS) announced a senior management change in a move designed to help re-establish the company’s growth trajectory.

February 8, 2017

Executive Moves

BioTime appoints Stephana Patton as general counsel

BioTime (NYSE MKT:BTX) has appointed Stephana Patton as general counsel, a newly created position. Reporting in her new role to Adi Mohanty, co-CEO, Dr. Patton will oversee all legal matters at the company.

February 7, 2017

Category - Executive Moves

Subscribe